According to the company’s press release, patients with PPP2R1A-mutated uterine cancers achieved partial responses in Aprea Therapeutics’ Phase 1 ACESOT-1051 trial of APR-1051, an oral WEE1 inhibitor, according to interim data the company released November 20 with a data cutoff date disclosed in the press release. According to the company’s press release, a subset of enrolled patients were evaluable for response, and those partial responses represent early signs of single-agent clinical activity reported for this program.

The finding matters because PPP2R1A mutations are a defined molecular subset in uterine cancer, and responses clustering there, rather than distributing randomly across a 43-patient evaluable pool, give the team a potential selection hypothesis to build dose-escalation and expansion decisions around. WEE1 inhibitors work by blocking a kinase that guards the G2/M cell-cycle checkpoint, forcing DNA-damaged cells into premature mitosis; tumors with specific replication-stress vulnerabilities are the logical target population, and PPP2R1A-mutated uterine cancer fits that rationale.

The data were presented at the 38th EORTC-NCI-AACR Symposium in Barcelona, alongside an updated corporate presentation filed with the SEC. The trial is an ongoing Phase 1 dose-escalation study of APR-1051 in patients with solid tumors, as described in the company’s press release. Aprea’s 8-K, signed by president and CEO Oren Gilad, confirms the data package and updated slides are now part of the public record.

At this stage, the trial is still enrolling and dose-escalation is ongoing, so the response count will shift with each cutoff. The specific marker worth tracking is whether the PPP2R1A signal holds as the evaluable population grows: if partial responses in that mutational subgroup accumulate at a rate disproportionate to their share of enrollment, Aprea has a molecular rationale to narrow its expansion cohorts and accelerate toward a dose that regulators and eventual partners can evaluate in a registration-enabling design.

Source link: https://www.sec.gov/Archives/edgar/data/1781983/000110465926130446/tm2630244d1_8k.htm

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.